Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH) has revised its profit forecast for the fiscal year 2025, anticipating a net profit after tax (NPAT) of between $320 million and $370 million. This forecast represents an increase from the previously indicated range of $310 million to $360 million provided in May.
The adjustment is attributed to the company's introduction of new products and ongoing changes in clinical practices. Fisher & Paykel, which specializes in acute and chronic respiratory care, surgery, and obstructive sleep apnea treatment, maintains its operating revenue guidance at approximately $1.9 billion to $2.0 billion.
CEO Lewis Gradon highlighted that the forecasted profit growth is supported by strong performance across all product lines and regions. The company has observed a positive response to new product launches and a high hospital census, with Northern Hemisphere seasonal hospitalizations extending into the start of the financial year. Additionally, Fisher & Paykel has noted progress in its gross margin improvement initiatives.
For the first half of FY2025, ending September 30, 2024, Fisher & Paykel projects revenue between $940 million and $950 million, with an NPAT ranging from $150 million to $160 million. This forecast reflects an approximate 18% increase in operating revenue and a 44% increase in NPAT compared to the first half of the 2024 fiscal year.